Syncona Ltd GBP · LSE:SYNC
Syncona Ltd GBP — Syncona — Investor Presentation (September 2022)
42 slides from Syncona Ltd GBP's investor presentation, September 2022
Slide 1: Investing to extend and enhance human life
Investing to extend and enhance human life Syncona corporate presentation September 2022 synconaltd.com Image Freeline labs, Stevenage
Slide 2: Cautionary statement
Cautionary statement This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity. In this statement, "presentation" means this document tog
Slide 3: A long-term vision: 10 years of Syncona
A long-term vision: 10 years of Syncona Co-founded in 2012 with The Wellcome Trust, our purpose is to invest to extend and enhance human life A decade of building global leaders Our growing track record 15 programmes taken into the clinic; 1 marketed product − Built 18 companies since − £943.7m depl
Slide 4: Capturing value in life science
Capturing value in life science Syncona utilises its model to capture world leading science and build sustainable companies Global transaction volume by expected years to market Number of biopharma deals greater than $1bn1 2005 to 2021 Pre-clinical Clinical stage 15 Syncona 14 13 converts non- 11 de
Slide 5: Executing a differentiated strategy
Executing a differentiated strategy 10 year targets Found Build Fund 2-3 new portfolio Proactively source Leverage expertise and Scale ambitiously, maintain companies p.a. globally competitive science, track record using Syncona significant ownership leveraging UK opportunity resource to drive succe
Slide 6: Market context
Market context
Slide 7: The promise of precision medicine
The promise of precision medicine Enables faster development, smaller, more capital efficient clinical trials and targeted commercial roll-out 30-60% A traditional drug may only be 30- 60% effective1 ‒ Traditional drug development can lead to ineffective drug development; it assumes all patients res
Slide 8: Syncona continues to identify opportunities across modalities
Syncona continues to identify opportunities across modalities Genetic medicines are unlocking diseases and streamlining drug development Cell and gene therapies have demonstrated transformative potential; significant opportunity ahead − Approved products and data to date have shown the transformatio
Slide 9: Portfolio
Portfolio
Slide 10: A differentiated portfolio
A differentiated portfolio Offering the potential for transformational efficacy in areas of high unmet medical need Cell therapy Gene therapy Engineered AAV gene therapy Biologics − Focused on key cell types and T-cell biology − Operating in key tissue compartments baked by − T-cell immunotherapy -
Slide 11: Diversified portfolio set to deliver key upcoming milestones
Diversified portfolio set to deliver key upcoming milestones Four at clinical stage, with a further three expected to enter the clinic in the next 12 months Upcoming clinical milestones Pre-clinical Phase I/II Phase III/Pivotal BLA* Launch Autolus – Initial results from obe-cel in r/r adult ALL expe
Slide 12: Positive momentum across a challenging macro backdrop
Positive momentum across a challenging £m Movement in listed holdings offset macro backdrop positive valuation changes in private portfolio Sentiment towards cell and gene therapy companies continues to impact listed holdings NAV of £1,331m, with life science portfolio valued at £562m and a capital
Slide 13: Gyroscope is third successful exit for Syncona
Gyroscope is third successful exit for Syncona Drives significant value for Syncona shareholders; Strong returns from investment in Gyroscope continued interest from pharma for Syncona companies Gyroscope was co-founded by Syncona in 2016 − Novartis agreed to acquire Gyroscope in December 2021 for u
Slide 14: Capital pool
Capital pool
Slide 15: Supporting our portfolio companies as they scale
Supporting our portfolio companies as they Money raised by portfolio companies since the beginning of FY2021/2 scale $m* 300 Syncona 3rd Party - Our balance sheet is a strategic and 250 competitive advantage; gives us flexibility to bring in specialist institutional investors at the 200 right time a
Slide 16: Strengthened capital pool
Strengthened capital pool Our strengthened capital base provides us with a strategic advantage, particularly in the current market environment Capital deployment to increase in FY2022/3 - £123.2m deployed into portfolio in FY2021/2, £38.0m in Q1 FY2022/3 - Expect to deploy £150-£250m of capital in F
Slide 17: Outlook
‘ Outlook
Slide 18: Building on our success
Building on our success Leveraging our successes and applying the lessons of the last 10 years to drive the business forward over the next decade Operating at scale − NAV of £1.3bn Where we − Capital pool of £769m are today \\\\\\\\\\\\\\\\\\\\ − 1,200+ employed at Syncona and its portfolio companie
Slide 19: Summary
Summary Syncona’s platform seeks to create value from the commercialisation of life science innovation CURRENT PORTOLIO ROLLING 10-YEAR TARGETS Syncona team has shown it can effectively manage the portfolio and deliver a return 18Portfolio companies 3 Companies sold since foundation, aggregate 4.6x
Slide 20: Appendix 1 – Syncona team
Appendix 1 – Syncona team
Slide 21: An expert multi-disciplinary investment team
An expert multi-disciplinary investment team Our unique skill set Scientific Commercial Company creation Investment Martin Murphy 1,2 Chris Hollowood 1 Edward Hodgkin 1,2 Elisa Petris 2 Co-founder, Chair, SIML CEO, SIML Senior Partner Lead Partner PhD PhD PhD PhD 21 years’ experience 20 years’ exper
Slide 22: Investment team supported by experts in life sciences and company building
Investment team supported by experts in life sciences and company building Markus John Leveraging the strength of clinical and operational experts - Joined in July 2021 Scientific Commercial Regulatory Business strategy - Former Global Medical Affairs Franchise Head at Roche Lisa Bright Markus John
Slide 23: Appendix 2 – Further market context
Appendix 2 – Further market context
Slide 24: Potential to transform the lives of patients
Potential to transform the lives of patients Kite/Gilead: engineered CAR-T cell therapy for adult relapse / refractory 43% of patients alive at five years post treatment2 3x overall survival rate of current standard of care at 12 Diffuse Large B-cell Lymphoma months3 Designed to halt a disease or re
Slide 25: Cell and gene therapies have the potential to disrupt the market
Cell and gene therapies have the potential to disrupt the market “… By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment Approved cell and gene therapies are expected to increase of the current pipeline and the clinical success rate
Slide 26: Appendix 3 – Portfolio companies
Appendix 3 – Portfolio companies
Slide 27: Financial review
Financial review Clinical Pre-clinical Drug discovery Portfolio company Fully diluted 31 March 2022 value Net invested/returned in the Valuation FX movement 30 June 2022 value Valuation basis % of ownership % £m (fair value) period £m change £m (fair value) (fair value)1,2 NAV 37.9% 59.8 - - 2.5 62.
Slide 28: Portfolio company outlook
Portfolio company outlook Upcoming milestones across the portfolio Company Status of pipelines Next steps Five ongoing clinical trials - Progress pivotal study in obe-cel / adult ALL, initial results in Q4 CY2022 with full data expected in H1 CY2023 - Announce longer-term follow-up data from AUTO1/2
Slide 29: Autolus Therapeutics
Autolus Therapeutics Applying a broad range of technologies to build Investment thesis a pipeline of precisely targeted T cell therapies - Syncona believes obe-cel has a designed to better recognise and attack cancer differentiated safety profile and improved persistence to address limitations of Bo
Slide 30: Anaveon
Anaveon Exploiting the power of cytokines to orchestrate Investment thesis immune responses by using protein - Developing a selective IL-2 agonist with engineering with the potential to create safe improved administration and toxicity and effective treatments for various diseases burden - Wide poten
Slide 31: Freeline Therapeutics
Freeline Therapeutics Seeking to deliver constant high protein Key management team Investment thesis expression levels with curative potential across Michael Parini, Chief Executive Officer (formerly Chief - To deliver therapies for a broad pipeline a broad pipeline of systemic diseases; Administrat
Slide 32: Achilles Therapeutics
Achilles Therapeutics Differentiated cell therapy approach targeting Key management team Investment thesis solid tumours utilising AI-enabled bioinformatics Iraj Ali, Chief Executive Officer (formerly Syncona Partner) Karl Peggs, Founder and Chief Medical Officer - TILs have shown convincing efficac
Slide 33: Quell Therapeutics
Quell Therapeutics Engineered cell therapy company addressing Investment thesis Key management team - Potential pipeline to treat serious, immune dysregulation Iain McGill, Chief Executive Officer (formerly on the Executive chronic conditions mediated by the Board Seat 2 (inc. Chair) Committee and a
Slide 34: SwanBio Therapeutics
SwanBio Therapeutics Developing leading-edge gene therapies to Investment thesis deliver dramatic clinical efficacy for the - Gene therapy has the potential to be treatment of neurological diseases transformational in neurology Board Seat 2 (inc. Chair) - Lead programme targeting AMN*, an Key manage
Slide 35: Purespring Therapeutics
Purespring Therapeutics Advancing gene therapies for the treatment of Investment thesis chronic renal diseases that are currently poorly - A number of chronic kidney diseases addressed with existing treatments are poorly addressed by existing therapies, which are primarily based Board Seat 2 (inc. C
Slide 36: Neogene Therapeutics
Neogene Therapeutics Pioneering the development of next- Investment thesis generation, fully personalised engineered T - The company is developing an cell therapies for a broad spectrum of engineered T Cell Receptor (TCR) therapeutic approach for solid cancers tumours based on a patient’s own Board
Slide 37: Resolution Therapeutics
Resolution Therapeutics Developing macrophage cell therapies to Key management team Investment thesis repair inflammatory organ damage, including Edward Hodgkin, Chair & Chief Executive Officer (Syncona - An opportunity to create the leading treatment of end-stage chronic liver disease Partner) infl
Slide 38: OMass Therapeutics
OMass Therapeutics Using novel biochemistry techniques, native Key management team Investment thesis mass spectrometry and custom chemistry to Rosamond Deegan, Chief Executive Officer (formerly Chief - Opportunity to develop differentiated deliver novel medicines against highly Business Officer at B
Slide 39: Clade Therapeutics
Clade Therapeutics Key management team Chad Cowan, PhD, Chief Executive Officer, Co-Founder (previously Harnessing iPSC immune cloaking and Investment thesis Co-founded and CSO, Sana Biotechnology, Co-Founder, Head of differentiation platform technology to deliver Research CRISPR Therapeutics) - Cla
Slide 40: Appendix 4 – Sustainability
Appendix 4 – Sustainability
Slide 41: Delivering positive and sustainable impact
Delivering positive and sustainable impact - d − £4.2m donated to charity in Our social impact − 19 portfolio company clinical trial sites across the UK − 900+ people employed by Syncona and its portfolio in the UK Responsible − Became a signatory to the UN Principles for Responsible Investment inve
Slide 42: The Syncona Foundation
The Syncona Foundation Supporting excellent charities that are meeting pressing needs within society, particularly those that are related to healthcare systems Focused on cancer, neuro-degenerative diseases, £40.6m Donations to charity since 20121 gene therapy. Alongside other health and society rel